TKPHF - Spark Newswire

1 minute read

Real-World Analysis Show Takeda’s Alofisel Clinical Remission Rate At Six-Months

Today, 4:21 PM

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel).

TAK

1 minute read

FDA Approves Takeda’s Vonvendi As Prophylactic Treatment In Bleeding Disorder

By Vandana Singh

Today, 4:21 PM

The

TAK

1 minute read

FDA Rejects Takeda’s Eosinophilic Esophagitis Candidate, Asks For Additional Study

By Vandana Singh

Today, 4:21 PM

Takeda Pharmaceutical Co Ltd (NYSE: TAK)

TAK

1 minute read

Novavax Files For Approval Of Its COVID-19 Vaccine In Japan

By Vandana Singh

Today, 4:21 PM

Novavax Inc (NASDAQ: NVAX) has

NVAX

1 minute read

Takeda, Shattuck Labs Terminate Immuno-Oncology Pact

By Vandana Singh

Today, 4:21 PM

Shattuck Labs Inc (NASDAQ: STTK) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) mutually agreed to terminate the Collaboration Agreement for SL-279252 and SL-115154.

STTK

1 minute read

Takeda’s 1H Sales Increase 13%, Reaffirms FY21 Outlook, Announces Share Buyback

By Vandana Singh

Today, 4:21 PM

Takeda Pharmaceutical Company Limited (NYSE:TAK) reported 1H FY21 sales of ¥1,794.4 billion, +12.8%. Underlying core revenue increased +6.8% Y/Y, driven…

TAK

1 minute read

Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout

By Vandana Singh

Today, 4:21 PM

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced the exercise of its option to acquire GammaDelta Therapeutics Limited, a T cell startup. A little…

TAK

1 minute read

Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs

By Vandana Singh

Today, 4:21 PM

Wave Life Sciences Ltd (NASDAQ:WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE:TAK) to discontinue discovery & research of preclinical…

TAK

1 minute read

Calithera Buys Two Oncology Candidates From Takeda For $45M

By Vandana Singh

Today, 4:21 PM

Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK).

CALA

1 minute read

Takeda Discontinues Two Mid-Stage Narcolepsy Trials

By Vandana Singh

Today, 4:21 PM

Takeda Pharmaceutical Company Limited (NYSE:TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral…

TAK

Feed Symbols: TKPHF